{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:29:20Z","timestamp":1762352960021,"version":"build-2065373602"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1245\/s10434-025-17745-4","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:06:15Z","timestamp":1752512775000},"page":"10261-10271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biochemical Recurrence in Pathologic T3\u20134 Prostate Cancer: Indications for Adjuvant Radiotherapy"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-784X","authenticated-orcid":false,"given":"Yu","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio Covas","family":"Moschovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shady","family":"Saikali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"17745_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341\u201352.","journal-title":"Lancet Oncol."},{"key":"17745_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413\u201321.","journal-title":"Lancet."},{"key":"17745_CR3","doi-asserted-by":"crossref","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331\u201340.","DOI":"10.1016\/S1470-2045(20)30456-3"},{"key":"17745_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396:1422\u201331.","journal-title":"Lancet."},{"key":"17745_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","volume":"35","author":"CC Parker","year":"2024","unstructured":"Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024;35:656\u201366.","journal-title":"Ann Oncol."},{"key":"17745_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","volume":"14","author":"C Deville Jr","year":"2024","unstructured":"Deville C Jr, Kamran SC, Morgan SC, Yamoah K, Vapiwala N. Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer. Pract Radiat Oncol. 2024;14:47\u201356.","journal-title":"Pract Radiat Oncol."},{"key":"17745_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamaoncol.2020.0565","volume":"6","author":"E MacDuffie","year":"2020","unstructured":"MacDuffie E, D\u2019Amico AV. Adjuvant vs salvage radiation therapy for high-risk prostate cancer following radical prostatectomy. JAMA Oncol. 2020;6:1165\u20136.","journal-title":"JAMA Oncol."},{"key":"17745_CR8","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"key":"17745_CR9","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1200\/JCO.20.03714","volume":"39","author":"D Tilki","year":"2021","unstructured":"Tilki D, Chen MH, Wu J, et al. Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2021;39:2284\u201393.","journal-title":"J Clin Oncol."},{"key":"17745_CR10","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.21.02800","volume":"40","author":"D Tilki","year":"2022","unstructured":"Tilki D, Chen MH, Wu J, Huland H, Graefen M, D\u2019Amico AV. Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J Clin Oncol. 2022;40:2186\u201392.","journal-title":"J Clin Oncol."},{"key":"17745_CR11","unstructured":"NCCN guideline: National Comprehensive Cancer Network. NCCN Guidelines Version 1. 2025: Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Retrieved 20 January 2025 at\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"17745_CR12","doi-asserted-by":"crossref","unstructured":"Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:245\u201353.","DOI":"10.3322\/caac.21391"},{"key":"17745_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2020.11.042","volume":"79","author":"MC Moschovas","year":"2021","unstructured":"Moschovas MC, Bhat S, Sandri M, et al. Comparing the approach to radical prostatectomy using the multiport da Vinci Xi and da Vinci SP robots: a propensity score analysis of perioperative outcomes. Eur Urol. 2021;79:393\u2013404.","journal-title":"Eur Urol."},{"key":"17745_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, et al. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u201352.","journal-title":"Am J Surg Pathol."},{"key":"17745_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","volume":"75","author":"M Assel","year":"2019","unstructured":"Assel M, Sjoberg D, Elders A, et al. Guidelines for reporting of statistics for clinical research in urology. Eur Urol. 2019;75:358\u201367.","journal-title":"Eur Urol."},{"key":"17745_CR16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.eururo.2007.01.015","volume":"51","author":"MN Simmons","year":"2007","unstructured":"Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175\u201384.","journal-title":"Eur Urol."},{"key":"17745_CR17","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1245\/s10434-016-5153-z","volume":"23","author":"M Kang","year":"2016","unstructured":"Kang M, Oh JJ, Lee S, Hong SK, Lee SE, Byun SS. Perineural invasion and lymphovascular invasion are associated with increased risk of biochemical recurrence in patients undergoing radical prostatectomy. Ann Surg Oncol. 2016;23:2699\u2013706.","journal-title":"Ann Surg Oncol."},{"key":"17745_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.urolonc.2009.06.017","volume":"29","author":"BI Chung","year":"2011","unstructured":"Chung BI, Tarin TV, Ferrari M, Brooks JD. Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival. Urol Oncol. 2011;29:314\u20138.","journal-title":"Urol Oncol."},{"key":"17745_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.euo.2023.11.021","volume":"7","author":"F Pellegrino","year":"2024","unstructured":"Pellegrino F, Falagario UG, Knipper S, et al. Assessing the impact of positive surgical margins on mortality in patients who underwent robotic radical prostatectomy: 20 years\u2019 report from the EAU Robotic Urology Section Scientific Working Group. Eur Urol Oncol. 2024;7:888\u201396.","journal-title":"Eur Urol Oncol."},{"key":"17745_CR20","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/cncr.23012","volume":"110","author":"RJ Hamilton","year":"2007","unstructured":"Hamilton RJ, Aronson WJ, Presti JC Jr, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database: results from the SEARCH database. Cancer. 2007;110:2202\u20139.","journal-title":"Cancer."},{"key":"17745_CR21","doi-asserted-by":"publisher","first-page":"830.e17","DOI":"10.1016\/j.urolonc.2021.04.031","volume":"39","author":"C W\u00fcrnschimmel","year":"2021","unstructured":"W\u00fcrnschimmel C, Wenzel M, Wang N, et al. Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. Urol Oncol. 2021;39:830.e17-e26.","journal-title":"Urol Oncol."},{"key":"17745_CR22","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.2006.10.4067","volume":"25","author":"TH Van der Kwast","year":"2007","unstructured":"Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25:4178\u201386.","journal-title":"J Clin Oncol."},{"key":"17745_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2019.07.001","volume":"76","author":"G Hackman","year":"2019","unstructured":"Hackman G, Taari K, Tammela TL, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 2019;76:586\u201395.","journal-title":"Eur Urol."},{"key":"17745_CR24","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956\u201362.","journal-title":"J Urol."},{"key":"17745_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial. Eur Urol. 2014;66:243\u201350.","journal-title":"Eur Urol."},{"key":"17745_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.euros.2024.09.007","volume":"69","author":"J Karwacki","year":"2024","unstructured":"Karwacki J, Stodolak M, D\u0142ubak A, et al. Association of lymphovascular invasion with biochemical recurrence and adverse pathological characteristics of prostate cancer: a systematic review and meta-analysis. Eur Urol Open Sci. 2024;69:112\u201326.","journal-title":"Eur Urol Open Sci."},{"key":"17745_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0022-5347(05)64284-X","volume":"168","author":"O Yossepowitch","year":"2002","unstructured":"Yossepowitch O, Sircar K, Scardino PT, et al. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002;168:2011\u20135.","journal-title":"J Urol."},{"key":"17745_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1569-9056(07)60632-0","volume":"6","author":"C Porter","year":"2007","unstructured":"Porter C, Walz J, Gallina A, et al. 634 Natural history of biochemical recurrence after radical prostatectomy for prostate cancer. Eur Urol Suppl. 2007;6:181.","journal-title":"Eur Urol Suppl."},{"key":"17745_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.eururo.2017.07.026","volume":"73","author":"N Fossati","year":"2018","unstructured":"Fossati N, Karnes RJ, Colicchia M, et al. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol. 2018;73:436\u201344.","journal-title":"Eur Urol."},{"key":"17745_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.euf.2015.06.008","volume":"1","author":"F Abdollah","year":"2015","unstructured":"Abdollah F, Karakiewicz PI, Gandaglia G, et al. Adjuvant radiotherapy in prostate cancer patients treated with surgery: the impact of age and tumor characteristics. Eur Urol Focus. 2015;1:191\u20139.","journal-title":"Eur Urol Focus."},{"key":"17745_CR31","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018\u201327.","journal-title":"Lancet."},{"key":"17745_CR32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1200\/JCO.2014.59.0026","volume":"33","author":"RB Den","year":"2015","unstructured":"Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33:944\u201351.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17745-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:17:38Z","timestamp":1762352258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17745-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["17745"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17745-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The requirement for written informed consent was waived by the Institutional Review Board of AdventHealth.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent Statement"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Adventhealth(protocol number: 237998).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval Statement"}}]}}